@article{oai:tsukuba.repo.nii.ac.jp:00049478,
 author = {関根, 郁夫 and SEKINE, Ikuo and 中澤, 健介 and NAKAZAWA, Kensuke and 佐藤, 浩昭 and SATOH, Hiroaki and 檜澤, 伸之 and HIZAWA, Nobuyuki and Shiozawa, Toshihiro and Aida, Yuka and Watanabe, Hiroko and Kurishima, Koichi},
 issue = {3},
 journal = {Case Reports in Oncology},
 month = {Sep},
 note = {Background: Sensitive-relapsed small-cell lung cancer (SCLC) is thought to be sensitive to chemotherapy; therefore, second-line chemotherapy is recommended. Although platinum rechallenge is performed in the second-line chemotherapy for sensitive-relapsed SCLC, it remains unclear whether such a strategy is effective. Methods: We retrospectively analyzed the outcome of rechallenge chemotherapy for sensitive-relapsed SCLC. The endpoints of this study were progression-free survival from the time of relapse (PFS-Re) and overall survival from the time of relapse (OS-Re). We also compared the toxicity profile of rechallenge chemotherapy to that of first-line chemotherapy. Results: Of the 133 SCLC patients who received first-line treatment, 20 patients satisfied the definition of sensitive relapse and received rechallenge chemotherapy. Combined carboplatin and etoposide was the most commonly used rechallenge regimen, and 17 (85%) received it at a reduced dose due to hematological toxicity during the first-line treatment. Median PFS-Re and OS-Re were 4.5 months (95% CI: 3.5–5.4) and 10.5 months (95% CI: 7.9–13.0), respectively. There was no association between dose adjustment and survival. The frequency of hematologic toxicity tended to be lower with rechallenge than first-line treatment. The incidence of grade 3 febrile neutropenia decreased from 40% in first-line treatment to 15% in rechallenge. Conclusion: Platinum rechallenge could be a useful second-line option for sensitive-relapsed SCLC, having favorable efficacy and safety. Dose adjustment at rechallenge based on the toxicity profile during the first-line chemotherapy could reduce toxicity without weakening efficacy.},
 pages = {622--632},
 title = {Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer},
 volume = {11},
 year = {2018},
 yomi = {セキネ, イクオ and ナカザワ, ケンスケ and サトウ, ヒロアキ and ヒザワ, ノブユキ}
}